Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : CEL383
Therapeutic Area : Gastroenterology
Study Phase : Phase I
Sponsor : AbbVie Inc
Deal Size : $250.0 million
Deal Type : Acquisition
AbbVie Acquires Celsius Therapeutics
Details : The Celsius Therapeutics acquisition will add CEL383, a potential first-in-class anti-Triggering Receptor Expressed on Myeloid Cells 1 antibody for inflammatory bowel disease, to AbbVie's portfolio.
Product Name : CEL383
Product Type : Antibody
Upfront Cash : $250.0 million
June 27, 2024
Lead Product(s) : CEL383
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Sponsor : AbbVie Inc
Deal Size : $250.0 million
Deal Type : Acquisition
Lead Product(s) : CEL383
Therapeutic Area : Gastroenterology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CEL383 is a potential first-in-class antibody directed towards Triggering Receptor Expressed on Myeloid Cells 1 that Celsius is advancing for the treatment of inflammatory bowel disease (IBD).
Product Name : CEL383
Product Type : Antibody
Upfront Cash : Inapplicable
March 08, 2023
Lead Product(s) : CEL383
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CEL383
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CEL383, an anti-TREM1 antibody, a myeloid target with a central role in inflammatory bowel disease. TREM1 is the first of these targets, an amplifier of mucosal inflammation that resides at the intersection of the microbiome and the immune system.
Product Name : CEL383
Product Type : Antibody
Upfront Cash : Inapplicable
February 27, 2023
Lead Product(s) : CEL383
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Discovery
Sponsor : Applied BioMath
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the agreement, Celsius Therapeutics will collaborate for the development of a systems pharmacology model of a monoclonal antibody for the treatment of inflammatory bowel disease (IBD).
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
April 10, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Discovery
Sponsor : Applied BioMath
Deal Size : Undisclosed
Deal Type : Collaboration
Servier and Celsius Therapeutics Announce Target Discovery Collaboration in Colorectal Cancer
Details : Under the terms of collaboration, Celsius will analyze hundreds of samples from defined CRC patient populations using its proprietary single-cell genomics platform and will work to identify and validate new drug targets during the three-year research per...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
December 21, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Gastroenterology
Study Phase : Discovery
Sponsor : University of Oxford
Deal Size : Undisclosed
Deal Type : Agreement
Details : Celsius will partner with leading academic scientists to access patient tissue samples and apply its proprietary single-cell genomics platform and machine learning capabilities to discover new insights into inflammatory bowel disease (IBD).
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
January 07, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Gastroenterology
Highest Development Status : Discovery
Sponsor : University of Oxford
Deal Size : Undisclosed
Deal Type : Agreement